AUTHORS
Sabarish Ayyappan, MD, Lu Chen, PhD2, Benjamin Heyman, MD3, Adam Braun, MD4, Azra Borogovac, MD5, John Baird, MD6, Avyakta Kallam, MBBS7, Leslie Popplewell, MD8, Geoffrey Shouse, DO PhD9, Swetha Thiruvengadam, MD10, James Godfrey, MD11, Victor Orellana-Noia, MD12, Brian Sworder, MD, PhD13, Alexandra Muir, BSN, RN14, Jennifer Shepphird, PhD15, Brian Hill, MD, PhD16, Reem Karmali, MD17, Taylor R. Brooks, MD18, Tycel Phillips, MD, FASCO19, Alexey V. Danilov, MD, PhD20
AFFILIATIONS
1 City of Hope Cancer Center Atlanta, Newnan Georgia, Georgia, United States
2 City of Hope Comprehensive Cancer Center, Duarte, California, United States
3 City of Hope Comprehensive Cancer Center, Duarte, California, United States
4 City of Hope Comprehensive Cancer Center, Duarte, California, United States
5 City of Hope Comprehensive Cancer Center, Duarte, California, United States
6 City of Hope Comprehensive Cancer Center, Duarte, California, United States
7 City of Hope Comprehensive Cancer Center, Duarte, California, United States
8 City of Hope Cancer Center Atlanta, Newnan Georgia, Georgia, United States
9 City of Hope Comprehensive Cancer Center, Duarte, California, United States
10 City of Hope Comprehensive Cancer Center, Duarte, California, United States
11 City of Hope Comprehensive Cancer Center, Duarte, California, United States
12 City of Hope Comprehensive Cancer Center, Duarte, California, United States
13 City of Hope Comprehensive Cancer Center, Duarte, California, United States
14 City of Hope Comprehensive Cancer Center, Duarte, California, United States
15 City of Hope Comprehensive Cancer Center, Duarte, California, United States
16 Cleveland Clinic, Cleveland, Ohio, United States
17 Robert H. Lurie Comprehensive Cancer Center , Northwestern University, Chicago, Illinois, United States
18 Cleveland Clinic, Cleveland, Ohio, United States
19 City of Hope Comprehensive Cancer Center, Duarte, California, United States
20 City of Hope Comprehensive Cancer Center, Duarte, California, United States
ABSTRACT
Background. Frontline therapy for mantle cell lymphoma (MCL) continues to evolve, with increasing interest in time-limited, chemotherapy-free approaches incorporating Bruton tyrosine kinase inhibitors (BTKi). Although covalent BTKi's are active in MCL, acquired resistance, in part mediated by mutations in BTK, as well as cumulative toxicities with long-term use remain important therapeutic challenges. Nemtabrutinib is a reversible, non-covalent BTKi with activity against both wild-type and C481-mutant BTK that has demonstrated promising safety and efficacy in relapsed/refractory (R/R) B-cell malignancies. We report interim results from this phase 2 study of nemtabrutinib plus rituximab as time-limited frontline therapy for previously untreated MCL (NCT06572618).
Methods. This ongoing open-label study enrolls adults ≥18 years with previously untreated, de novo MCL unsuitable for or unwilling to receive intensive induction therapy. Patients with high-risk genomic features, including TP53 aberrations and complex karyotype, are eligible. Patients receive induction with nemtabrutinib 65 mg orally once daily continuously plus rituximab 375 mg/m² intravenously weekly during cycle 1 and on day 1 of cycles 2–6. Patients achieving a partial response (PR) or complete response (CR) continue onto maintenance therapy with daily nemtabrutinib and rituximab every 2 cycles for up to 24 cycles. Each cycle is 28 days. Patients without PR/CR after induction are considered for alternative therapy; continued single agent nemtabrutinib beyond 30 cycles is permitted at investigator discretion. The primary endpoint is CR rate at any point during the study. Expected accrual is 24 response-evaluable patients. The sample size is designed to detect a promising CR rate of 80%. Secondary endpoints include overall response rate (ORR), progression-free survival (PFS), overall survival (OS), duration of response, and safety. Exploratory analyses include minimal residual disease assessment by clonoSEQ, T-cell studies, and tumor mutational profiling from biopsy specimens.
Results. As of 7/2/2026, 17 patients were enrolled. Median age was 77 years (range, 54-86), 12 (71%) patients were male, and 15 (88%) patients had an ECOG performance status of 0–1. Three patients had aberrant TP53 (2 TP53mut, 1 del(17p)), 3 patients had complex karyotype, 9 (47%) patients had at least high-intermediate-risk MIPIc score and 9 had Ki-67 ≥30%.
Thirteen patients are evaluable for response by Lugano criteria: ORR is 100% (11 CR and 2 PR); best response by end of induction is 9 CR, 3 PR, and 1 SD; 3 patients are pending treatment/response evaluation. One patient is inevaluable for response due to terminating after 2 cycles and did not receive at least 50% of nemtabrutinib dose for one cycle. Fifteen patients remain on therapy having received 1-14 (median 10) months of therapy. Two patients have terminated protocol treatment: one due to rash after 2 cycles and one due to death from myocardial infarction during maintenance, 15 months from treatment start. No disease progression was reported. 12-month PFS and OS were 100%.
Sixteen patients are evaluable for toxicity. Most common all grade attributable toxicities were rash (63%), constipation (44%), dysgeusia (44%) and neutropenia (31%; use of growth factors was allowed). Most common attributable grade ≥3 toxicities were neutropenia (25%), rash (25%), urinary tract infection (UTI; 13%) and hypertension (13%). There were 15 serious adverse events; 8 were at least possibly related to study drug (UTI, neutropenia, fever, lung infection; none required hospitalization). Eight (50%) patients underwent dose modifications of nemtabrutinib due to adverse events, including neutropenia, rash, and dysgeusia. One additional patient (6%) discontinued treatment for AE (rash).
Conclusions. A combination of non-covalent BTKi nemtabrutinib and rituximab is an efficacious chemotherapy-free frontline regimen for patients with previously untreated MCL. The preliminary CR rate was 90%. Adverse events of treatment were manageable, and safety findings were consistent with the known toxicity profile of nemtabrutinib, with updated efficacy and safety data to be presented. The study continues to enroll participants.
Supported in part by a research grant from Investigator-Initiated Studies Program of Merck Sharp & Dohme LLC. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme LLC.
DISCLOSURES
Sabarish Ayyappan, MD: Regeneron Pharmaceuticals, Inc. - Honoraria; AbbVie - Honoraria; ADC Therapeutics - Honoraria; AstraZeneca - Honoraria; BeOne - Honoraria; Fate Therapeutics - Honoraria; Peereview - Honoraria; Genentech - Honoraria; Beigene - Honoraria; Iowa Oncology Society - Honoraria; Seattle Genetics - Honoraria; Genmab - Honoraria; Incyte - Honoraria; Seattle Genetics - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Acrotech - Consultancy (Includes expert testimony); Fate Therapeutics - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Regeneron Pharmaceuticals, Inc. - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony)